METHOD OF TREATING PROSTATE CANCER Russian patent published in 2020 - IPC A61N5/10 A61K38/09 A61P35/00 G01N33/574 G01N33/78 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncourology, radiotherapy, and can be used for treating prostate cancer. It is followed by androgen deprivation with zoladex, control of prostate-specific antigen PSA and blood testosterone for correction of treatment, and radiation therapy. Androgen deprivation is performed until blood PSA level is less than 1 ng/ml. Blood testosterone is then determined. If its value is less than 20 ng/dl, Zoladex is administered for following 6 months and the split radiotherapy to 66–70 Gy. If blood testosterone level is detected within 20 ng/dl to 50 ng/dl, administration of Zoladex and daily administration of 100 mg of Casodex for next 9 months and radiotherapy with a split course to total boost dose 70–74 Gy are prescribed. If blood testosterone level is more than 50 ng/dl, androgen deprivation with Zoladex and daily administration of 150 mg Casodex within next 9 months. Every 3 months blood testosterone level is examined and only after testosterone level drops to less than 50 ng/dl, radiation therapy is prescribed by continuous course to total boost dose 76 Gy.

EFFECT: method provides higher clinical effectiveness ensured by individualisation of the androgen deprivation and radiation therapy, including with respect to the total radiation dose, which enables reducing the probability of severe radiation complications from the bladder, rectum and, as a result, higher comfort of such patients and optimization of financial costs for their treatment, increased recurrence-free life.

1 cl, 7 ex